Stockscreener 앱 받기
59.31
7.39%
4.08
시간 외 거래:
60.00
0.69
+1.16%
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
SRPT Quantitative Stock Analysis - Nasdaq
Sarepta: Gene therapy Elevidys has given ‘hope’ to DMD community - Muscular Dystrophy News
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - MSN
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results | SRPT Stock News - GuruFocus
Sarepta Therapeutics To Announce First Quarter 2025 Financial Results - marketscreener.com
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results - Business Wire
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? - Insider Monkey
ALDX Investors Have Opportunity to Join Aldeyra Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
11 Most Promising Long-Term Stocks According to Analysts - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Piper Sandler Cuts Price Target for Sarepta (SRPT) Amid Elevidys Sales Concerns | SRPT Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Thera - NatLawReview.com
Sarepta (SRPT) Price Target Lowered by BofA Ahead of Q1 Earnings | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Sarepta Therapeutics’ (SRPT) Neutral Rating Reiterated at HC Wainwright - Defense World
Cancer Retains Top Spots In Alliance Deal Volume, Value - insights.citeline.com
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating - marketscreener.com
FDA OKs trial of SRP-9005 gene therapy for LGMD type 2C - Muscular Dystrophy News
Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne - Endpoints News
Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week - Yahoo Finance
Lobbying Update: $320,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements - TipRanks
SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies - Zacks Investment Research
Sarepta (SRPT) Advances Gene Therapy Trials for Muscular Dystrop - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials By Investing.com - Investing.com Nigeria
Sarepta Therapeutics Announces Pipeline Progress For Multiple Limb-Girdle Muscular Dystrophy Programs - marketscreener.com
Sarepta Therapeutics Announces Pipeline Progress for Multiple Li - GuruFocus
FDA clears Sarepta to proceed with LGMD gene therapy trials - Investing.com
Sarepta Therapeutics (SRPT) Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - StreetInsider
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - itemonline.com
Sarepta Expands Rare Disease Pipeline: FDA Green Light for New LGMD Trial - Stock Titan
Trump health policy uncertainty sends biotech sector into deeper slump - MarketScreener
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by O Shaughnessy Asset Management LLC - Defense World
Morgan Stanley Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $182.00 - Defense World
Wells Fargo Initiates Coverage of Sarepta Therapeutics (BMV:SRPT) with Overweight Recommendation - Nasdaq
SRPT Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - PR Newswire
Indo-Asian News Service - Indo-Asian News Service (IANS)
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) with Overweight Recommendation - Nasdaq
Wells Fargo Initiates Coverage of Sarepta Therapeutics (SRPT) wi - GuruFocus
Sarepta stock wins bullish view at Wells Fargo (SRPT:NASDAQ) - Seeking Alpha
Sarepta (SRPT) Price Target Cut by Morgan Stanley Ahead of Earni - GuruFocus
Cns Specific Antisense Oligonucleotide Market Is Booming - openPR.com
Wells Fargo Starts Sarepta (SRPT) with Overweight Rating, Targets $115 | SRPT Stock News - GuruFocus
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Zacks Research Issues Pessimistic Forecast for SRPT Earnings - Defense World
Sarepta Therapeutics (SRPT) Sees Price Target Reduction by Gugge - GuruFocus
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb - Yahoo Finance
Q1 EPS Estimate for Sarepta Therapeutics Reduced by Analyst - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025 - CGTLive®
Independent DMC Concludes that Risk-Benefit Ratio for Sarepta’s DMD Gene Therapy Elevidys Remains Favorable - CGTLive®
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm - Business Wire
Sarepta (SRPT) Shares Fall Over 6% Following EMA Clinical Hold - GuruFocus
Sarepta (SRPT) Seeks Continuation of Elevidys Trials Amid Safety Review - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) versus Cellectar Biosciences (NASDAQ:CLRB) Financial Analysis - Defense World
Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death - MSN
1.00%
자본화:
|
볼륨(24시간):